anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Tirofiban
Trial phase: Phase 2
ATC code: B01AC17
SMILES: CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 18
Group description: Patient receive 325mg ASA orally and loading does of 600mg Clopidogrel at time of procedure with addition of IV GP IIb/IIIa inhibitor bolus intra procedurally
Eligibility criteria:
Inclusion Criteria:

Age older than 18 years
Scheduled for elective or ad-hos PCI
Aspirin use daily for greater or equal to one week
Aspirin resistant (ARU greater than or equal to 550 on Verify Now-ASA

Exclusion Criteria:

Pre-procedural elevation of cardiac biomarkers (CK-MB greater or equal to 10.4ng/dl or Tnl greater or equal to 0.4ng/dl
administration of any GP IIb/IIIa inhibitor, anticoagulation or lytic therapy in the previous 30 days
Ongoing bleeding or bleeding diathesis, contraindications for anticoagulation or increased bleeding risk or history of bleeding in the last eight weeks
Previous stroke or transient ischemic attack or any intracranial pathology in the last six months, major surgery or trauma within the previous six weeks
Platelet count less than hundred thousand per cubic millimeter or hematocrit <33% or hemoglobin <11 g per deciliter
Subjects who received full dose low molecular weight heparin within six hours prior to randomization
Allergy or intolerance to any of the study drugs or the presence of any serious comorbidity with life expectancy of ≤1year
Scheduled for saphenous vein graft intervention, chronic total occlusions or with impaired renal function (eGFR<60ml/min) or patients who were taking anticoagulants or antiplatelet agents other than aspirin and clopidogrel or nonsteroidal anti-inflammatory drugs within two weeks before the PCI procedure
Intervention: Testosterone
Trial phase: Phase 1
ATC code: G03BA03 | G03EA02
SMILES: [H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@@H](O)CC[C@@]21[H]
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 40
Group description: Testosterone Transdermal System was applied daily starting at 4 mg, titratable to 6 mg or 2 mg based on testosterone serum concentration.
Eligibility criteria:
Inclusion Criteria:

Males in good general health, 18 years of age or older.
Have a previously documented testosterone deficiency.
Willing and able to comply with the requirements of the protocol.

Exclusion Criteria:

Have a history of intolerance to Androderm or other testosterone products.
Prostate specific antigen (PSA) level ≥ 4.0 ng/mL
Prostate cancer or severe benign prostatic hypertrophy (BPH)
Have significant abnormalities in the physical examination at screening.
Have current dermatological disease, skin damage or blemishes.
Have participated in an investigational drug study within 30 days prior to screening.
Intervention: Gadobutrol
Trial phase: Phase 3
ATC code: V08CA09
SMILES: O=C([O-])CN1CCN(CC(=O)[O-])CCN(C(CO)C(O)CO)CCN(CC(=O)[O-])CC1.[Gd+3]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 439
Group description: Participants first received an unenhanced magnetic resonance mammography (MRM), followed by a gadobutrol-enhanced MRM. Gadobutrol was administered at the standard dose of 0.1 mmol/kg body weight (bw) [0.1 ml/kg bw] as an intravenous injection at a rate of 2 ml/sec. unenhanced MRM (UMRM) and combined unenhanced and contrast (gadobutrol)-enhanced MRM (CMRM) image sets were evaluated in a randomized fashion. After the evaluation of the UMRM or CMRM the respective X-ray mammography (XRM) was added and evaluated together with the UMRM images.
Eligibility criteria:
Inclusion Criteria:

Recent histologically proven diagnosis of breast cancer after having obtained X-Ray Mammography (XRM) of both breasts (according to American College of Radiology [ACR] and performed no longer than 6 weeks prior to enrollment into the study) and has been referred for a contrast-enhanced Magnetic Resonance Mammography (MRM) prior to surgery of the breast.

if female, a digital XRM is required if any of the following criteria is met:

a. patient is younger than 50 years;
b. patient has heterogeneously or extremely dense breasts;
c. is not post-menopausal (post-menopause defined as at least 12 months prior to inclusion without menstruation).
if female of childbearing potential, MRM should be performed on the 7-14th day of the menstrual cycle.
has an estimated glomerular filtration rate (eGFR) value >/= 60 mL/min/1.73m^2 derived from a serum creatinine result within 2 weeks prior to study enrollment.

Exclusion Criteria:

is a female patient who is pregnant or lactating
has any contraindication to the MRM examination (e.g. metal implants, phobia) or the use of gadolinium-containing contrast agents.
has received any contrast agent within 24 hours prior to the study MRM, or is scheduled to receive any contrast agent within 24 hours after the study MRM.
has severe cardiovascular disease (e.g., known long QT syndrome, acute myocardial infarction [< 14 days], unstable angina, congestive heart failure New York Heart Association class IV) or acute stroke (< 48 hours)).
has acute renal insufficiency of any severity due to hepato-renal syndrome or in the peri-operative liver transplantation period or who has acute or chronic moderate or severe renal insufficiency (glomerular filtration rate < 60 mL/min/1.73m^2).
has received chemotherapy or hormonal therapy for breast cancer within 6 months.
has received hormone replacement therapy within 4 weeks prior to study drug administration.
is scheduled or likely to require a surgery and/or biopsy in the time period up to 24 hours following study drug application
has prior excisional biopsy or breast surgery less than 6 months before enrollment and between XRM and study MRM
Intervention: Brimonidine Tartrate
Trial phase: Not Applicable
SMILES: Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 23
Group description: Patients who exhibited retinal vascular dysregulation at the initial visit. Intervention: brimonidine 0.15% three times per day for 8 weeks.

Alphagan (brimonidine) 0.15%: One drop in each eye three times a day for 8 weeks.
Eligibility criteria:
Inclusion Criteria:

Eligible subjects will have no history of IOP > 24 mm Hg in either eye.
All subjects will have open angles on gonioscopy with the filtering portion of the trabecular meshwork visible for 360° in both eyes.
Previously or newly diagnosed patient are required to have HVFs that are reliable and show loss consistent with nerve fiber layer atrophy.
Patients with glaucoma-like discs (CDR>0.7 in either eye) and normal/reliable visual fields who the PI has opted to observe without treatment will enter the study if they meet the other study criteria.
In order to facilitate the retinal blood flow measurements, only subjects with refractive error within the range -10 to +10 diopters, no lens opacities greater than 1+ cortical spokes or 2+ nuclear sclerosis, and pupillary dilation of at least 6 mm following mydriasis will be included.

Exclusion Criteria:

Patients with evidence of exfoliation or pigment dispersion syndrome in either eye.
Patients with a cup/disc ratio > 0.8.
Known history of allergy to brimonidine.
Patients already on treatment with brimonidine will be excluded from the study.
Diabetic retinopathy.
History of ocular laser or incisional surgery in either eye.
Use of systemic alpha-2 blockers.
Pregnant or planning to become pregnant.
Intervention: Atomoxetine
Trial phase: Phase 3
ATC code: N06BA09
SMILES: CNCC[C@@H](Oc1ccccc1C)c1ccccc1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 134
Group description: Atomoxetine Hydrochloride (Strattera) was administered orally once-daily at approximately 7:00am for 9 weeks (4-week dose optimization period and a 5-week dose maintenance period) at weight adjusted doses of 10 mg to 100 mg.
Eligibility criteria:
Inclusion Criteria:

Subject has had an historical or current inadequate response to methylphenidate (MPH) treatment. Inadequate response includes but is not limited to the presence of some residual symptoms, with associated impairment inadequate duration of action and/or variability of symptom control, and/or Investigator feels that the subject may derive benefit from an alternative drug treatment to MPH therapy.
Subject is a male or female aged 6-17 years inclusive at the time of consent
Subject must meet Diagnostic and Statistical Manual of Mental Disorders, fourth edition. - Text Revision (DSM IV TR) criteria for a primary diagnosis of ADHD based on a detailed psychiatric evaluation
Subject must have a baseline ADHD-RS-IV total score 28.

Exclusion Criteria:

Subject has taken more than 1 MPH treatment (for example, 2 or more different MPH treatments). Examples include but are not limited to RITALIN immediate release (IR) and EQUASYM IR; MEDIKINET IR and CONCERTA; RITALIN long-acting LA and CONCERTA. Note: this does not include subjects who have taken IR MPH for dose titration on a short-term basis (for example, £4 weeks) with an adequate response
In the Investigator's judgement, subject has failed to respond to more than 1 previous course(s) of MPH treatment. Failure to respond includes worsening of symptoms or no change/minimal improvement of symptoms.
Subject has previously been exposed to STRATTERA or to amphetamine therapy
Subject has previously demonstrated intolerable side effects to 1 MPH treatment which limited titration to acceptable efficacy or that required a decrease in dose resulting in unacceptable tolerability and/or efficacy
Subject has a current, controlled (requiring a restricted medication) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as any severe comorbid Axis II disorder or severe Axis I disorder or other symptomatic manifestations, such as agitated states, marked anxiety, or tension that, in the opinion of the examining physician, will contraindicate treatment with SPD489 or STRATTERA or confound efficacy or safety assessments.
Subject has a conduct disorder. Oppositional Defiant Disorder is not exclusionary.
Intervention: SODIUM CHLORIDE
Trial phase: Not Applicable
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 12
Group description: Group A: Saline group , infusion of saline intravenously

Group A: Saline Group: Saline continuous infusion
Eligibility criteria:
Inclusion Criteria:

Gender: Female
Age: 18-65 years
Non-pregnant, non-lactating
Surgery: Outpatient hysteroscopic Novasure® endometrial ablation
Language: English speaking
Consent: Obtained

Exclusion Criteria:

Patient refusal
Under 18 or over age 65
Non-English Speaking
Pregnancy, Breast feeding
Hysteroscopic procedures using Thermachoice® ablation device
Chronic use or addiction to opiates, sedatives, non-opiate analgesics
History of heavy alcohol usage (>4 drinks/day)
Significant cardiovascular or pulmonary disease
Psychiatric or emotional disorder
Allergy to anesthetic agents utilized in the protocol
Glaucoma
Thyrotoxicosis
Intervention: Ketamine
Trial phase: Not Applicable
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 9
Group description: Group B: Infusion of ketamine 1% intravenously

Group B: 1% Ketamine group: Administration of 1% ketamine intravenously.
Eligibility criteria:
Inclusion Criteria:

Gender: Female
Age: 18-65 years
Non-pregnant, non-lactating
Surgery: Outpatient hysteroscopic Novasure® endometrial ablation
Language: English speaking
Consent: Obtained

Exclusion Criteria:

Patient refusal
Under 18 or over age 65
Non-English Speaking
Pregnancy, Breast feeding
Hysteroscopic procedures using Thermachoice® ablation device
Chronic use or addiction to opiates, sedatives, non-opiate analgesics
History of heavy alcohol usage (>4 drinks/day)
Significant cardiovascular or pulmonary disease
Psychiatric or emotional disorder
Allergy to anesthetic agents utilized in the protocol
Glaucoma
Thyrotoxicosis
Intervention: Imipramine Pamoate
Trial phase: Not Applicable
SMILES: CN(C)CCCN1c2ccccc2CCc2ccccc21.CN(C)CCCN1c2ccccc2CCc2ccccc21.O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 39
Group description: First 75 mg imipramine pamoate capsule, then 75 mg Tofranil-PM capsule (after washout period)

Imipramine Pamoate: 75 mg capsule
Eligibility criteria:
Inclusion Criteria:

No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening

Exclusion Criteria:

Positive test for HIV, Hepatitis B, or Hepatitis C.
Treatment with known enzyme altering drugs.
History of allergic or adverse response to imipramine pamoate or any comparable or similar product.
Intervention: Imipramine Pamoate
Trial phase: Not Applicable
SMILES: CN(C)CCCN1c2ccccc2CCc2ccccc21.CN(C)CCCN1c2ccccc2CCc2ccccc21.O=C(O)c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 39
Group description: First 75 mg Tofranil-PM capsule, then 75 mg imipramine pamoate capsule (after washout period)

Imipramine Pamoate: 75 mg capsule
Eligibility criteria:
Inclusion Criteria:

No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening

Exclusion Criteria:

Positive test for HIV, Hepatitis B, or Hepatitis C.
Treatment with known enzyme altering drugs.
History of allergic or adverse response to imipramine pamoate or any comparable or similar product.
Intervention: SODIUM CHLORIDE
Trial phase: Phase 2
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 157
Group description: Placebo (Normal saline) equally divided and administered to each lateral prostatic lobe.
Eligibility criteria:
Inclusion Criteria:

Clinical enlargement of the prostate gland
Body weight ≥ 50 kg or 110 lbs

Exclusion Criteria:

History of chronic prostatitis
History of two or more urinary tract infections in the past year or one in the last 6 months
History of bladder stones
History of previous prostate surgery
History of bladder cancer or prostate cancer
Any previous or current usage of botulinum toxin therapy of any serotype for any urological condition
Botulinum toxin therapy of any serotype for any non-urological condition or usage (e.g., cosmetic) during the previous 12 weeks prior to study entry
Intervention: LOTEPREDNOL ETABONATE
Trial phase: Phase 2
ATC code: S01BA14
SMILES: [H][C@@]12CC[C@](OC(=O)OCC)(C(=O)OCCl)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Loteprednol etabonate ophthalmic suspension dosed four times/day
Eligibility criteria:
Inclusion Criteria:

Positive history of ocular allergies and positive skin test reaction to cat hair, cat dander, grasses, ragweed, and/or trees within the past 24 months.
Calculated best-corrected visual acuity of 0.70 logMAR or better in each eye as measured using the ETDRS chart.
Positive bilateral conjunctival allergen challenge(CAC)reaction within 10 minutes of instillation of the last titration of allergen at visit 1.
Positive bilateral CAC reaction in 1 out of 3 time points for the initial and re-challenge at visit 2.

Exclusion Criteria:

Known contraindications or sensitivities to the study medication or its components.
Any ocular condition that, in the opinion of the investigator, could affect the subjects safety or trial parameters.
Use of disallowed medications during the period indicated prior to study enrollment or during the study.
Intervention: Levocarnitine
Trial phase: Phase 3
ATC code: A16AA01
SMILES: C[N+](C)(C)CC(O)CC(=O)[O-]
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 33
Group description: Carnitine 2 days preoperatively and 4 days postoperatively

Carnitine: Carnitine 2 days preoperatively and 4 days postoperatively
Eligibility criteria:
Inclusion Criteria:

Patients undergoing on-pump cardiac surgery

Exclusion Criteria:

Off-pump cardiac surgery procedure
AF before the procedure
Recent infection and/or infectious endocarditis
Presence of neoplasia
Chronic renal failure with creatinine>2.3 mg/dl
Hepatic failure
Autoimmune disease and/or disease that brings about a systematic inflammatory response
Thyroid disease
Systematic use of supplements that contain vitC or carnitine
The use of NSAIDs other than aspirin for a time period up to one month before the procedure
Intervention: ASCORBIC ACID
Trial phase: Phase 3
ATC code: A11GA01 | A11GB01 | B03AA10 | G01AD03 | S01XA15
SMILES: O=C1OC(C(O)CO)C(O)=C1O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 33
Group description: Vitamin C 2 days preoperatively and 4 days postoperatively

Vitamin C: Vitamin C 2 days preoperatively and 4 days postoperatively
Eligibility criteria:
Inclusion Criteria:

Patients undergoing on-pump cardiac surgery

Exclusion Criteria:

Off-pump cardiac surgery procedure
AF before the procedure
Recent infection and/or infectious endocarditis
Presence of neoplasia
Chronic renal failure with creatinine>2.3 mg/dl
Hepatic failure
Autoimmune disease and/or disease that brings about a systematic inflammatory response
Thyroid disease
Systematic use of supplements that contain vitC or carnitine
The use of NSAIDs other than aspirin for a time period up to one month before the procedure
Intervention: Clopidogrel
Trial phase: Phase 1
ATC code: B01AC04
SMILES: [H][C@@](C(=O)OC)(c1ccccc1Cl)N1CCc2sccc2C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Clopidogrel 600 mg taken orally, day one, single dose (Loading Dose [LD])
Eligibility criteria:
Inclusion Criteria:

Men or women ≥18 to <80 years of age who present with any one of the following:
symptoms of Acute Coronary Syndromes (ACS)
clinical symptoms of angina, or a positive stress test or who return for routine follow up angiography post stent placement in whom co-administration of aspirin and a thienopyridine (that is, clopidogrel, ticlopidine, or prasugrel) is not contraindicated

Exclusion Criteria:

Those presenting with ST-elevation MI (STEMI)
histories of refractory ventricular arrhythmias
an implanted defibrillator device
congestive heart failure (NYHA Class III or above) within 6 months prior to screening
significant hypertension
subjects with a history or clinical suspicion of cerebral vascular malformations, transient ischaemic attack, or stroke
bleeding disorders
women known to be pregnant, who have given birth within the past 90 days, or who are breastfeeding
Intervention: Prasugrel
Trial phase: Phase 1
ATC code: B01AC22
SMILES: CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Prasugrel 60 mg taken orally, day one, single dose (Loading Dose [LD])
Eligibility criteria:
Inclusion Criteria:

Men or women ≥18 to <80 years of age who present with any one of the following:
symptoms of Acute Coronary Syndromes (ACS)
clinical symptoms of angina, or a positive stress test or who return for routine follow up angiography post stent placement in whom co-administration of aspirin and a thienopyridine (that is, clopidogrel, ticlopidine, or prasugrel) is not contraindicated

Exclusion Criteria:

Those presenting with ST-elevation MI (STEMI)
histories of refractory ventricular arrhythmias
an implanted defibrillator device
congestive heart failure (NYHA Class III or above) within 6 months prior to screening
significant hypertension
subjects with a history or clinical suspicion of cerebral vascular malformations, transient ischaemic attack, or stroke
bleeding disorders
women known to be pregnant, who have given birth within the past 90 days, or who are breastfeeding
Intervention: Prasugrel
Trial phase: Phase 1
ATC code: B01AC22
SMILES: CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 8
Group description: Prasugrel 30 mg taken orally, day one, single dose (Loading Dose [LD])
Eligibility criteria:
Inclusion Criteria:

Men or women ≥18 to <80 years of age who present with any one of the following:
symptoms of Acute Coronary Syndromes (ACS)
clinical symptoms of angina, or a positive stress test or who return for routine follow up angiography post stent placement in whom co-administration of aspirin and a thienopyridine (that is, clopidogrel, ticlopidine, or prasugrel) is not contraindicated

Exclusion Criteria:

Those presenting with ST-elevation MI (STEMI)
histories of refractory ventricular arrhythmias
an implanted defibrillator device
congestive heart failure (NYHA Class III or above) within 6 months prior to screening
significant hypertension
subjects with a history or clinical suspicion of cerebral vascular malformations, transient ischaemic attack, or stroke
bleeding disorders
women known to be pregnant, who have given birth within the past 90 days, or who are breastfeeding
Intervention: OMEGA-3-ACID ETHYL ESTERS
Trial phase: Not Applicable
ATC code: C10AX06
SMILES: CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OCC.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 13
Group description: Oral Omega-3-acid ethyl esters: 1 gram capsule by mouth four times daily for 45 days
Eligibility criteria:
Inclusion Criteria:

Age > 18 years
Typical symptoms of dry eye (photophobia, burning, foreign body sensation, blurred vision improved with blinking)
Schirmer Test < 8 mm/5 minutes
Fluorescein tear break-up time < 8 seconds
No current use of dry eye treatment (except artificial lubrication)
Signature on consent form

Exclusion Criteria:

Infectious keratoconjunctivitis or inflammatory disease unrelated to dry eye
Eyelid or eyelash abnormalities
Alteration of the nasolacrimal apparatus
Treatment with drugs affecting tearing
Concomitant ocular therapies
Topical ophthalmic steroids taken during the 4 weeks before the study
Pregnant/breast-feeding women
History of liver disease
History of fish and/or shellfish allergy or hypersensitivity
History of corn allergy or hypersensitivity
Treatment with systemic anticoagulation therapy
Patients with bleeding disorders or those receiving anticoagulation (e.g., warfarin, enoxaparin, dipyridamole, clopidogrel)